| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $1.1M | +12.6% | -3.3% |
| SG&A Expense | $1.1M | +38.7% | +23.5% |
| Operating Income | -$2.2M | -24.3% | -8.5% |
| Net Income | -$2.2M | -24.4% | -9.5% |
| EPS (Basic) | -$0.11 | -10.0% | +21.4% |
| EPS (Diluted) | -$0.11 | -10.0% | +21.4% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.2M | +357.5% | +30.1% |
| Current Assets | $5.3M | +322.9% | +30.1% |
| Total Assets | $12.3M | +46.8% | +6.0% |
| Current Liabilities | $1.2M | +1.1% | +1.0% |
| Total Liabilities | $1.2M | +0.0% | +0.0% |
| Stockholders' Equity | $11.1M |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.6M | -128.6% | — |
| Capital Expenditures | $84K | -0.0% | — |
| Investing Cash Flow | -$84K | +0.0% | — |
| Financing Cash Flow | $7.3M | +487.8% | — |
| Free Cash Flow | -$3.7M | -122.1% | — |
| +6.6% |